Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models

Documenti analoghi

• Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report
  di: Li Liu, et al.
  Pubblicazione: (2026)
• CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer
  di: Shini Liu, et al.
  Pubblicazione: (2024)
• The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design.
  di: Wang, Yinghan, et al.
  Pubblicazione: (2025)
• Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells
  di: Hiromi Muraoka, et al.
  Pubblicazione: (2025)
• A Dual‐Function Mitochondria‐Targeted Polyoxometalate Nanomicelle Boosts Pyroptosis‐Dependent Antitumor Immune Response in Triple‐Negative Breast Cancer
  di: Qingqing Dou, et al.
  Pubblicazione: (2026)